We have updated the ordering process to allow all products and services to be purchased with a single PO, please address all POs to Horizon Discovery Biosciences Limited. Contact us for assistance.

Horizon Sign Agreement With Novartis Institute of Biomedical Research

03 Dec 2008

Horizon Discovery (Horizon) today announced it has signed a commercial agreement with Novartis Institute of Biomedical Research relating to the ongoing access to a panel of X-MAN™ cell-lines.

X-MAN ‘Mutant And Normal’ human isogenic cell-lines are the first genetically-defined in-vitro models of human cancer and their matched normal cell-types, that help accelerate and rationalize the discovery of novel ‘personalised’ medicines and their optimal assessment in clinical trials.

The agreement covers the ongoing license of a panel of eight X-MAN cell lines that represent model genotypes of interest to Novartis.

“Chris Torrance, CEO of Horizon says “it is our aim to get our novel ‘patient-relevant’ X-MAN cancer models rapidly into the real world drug discovery arena and signing up Novartis is a big coup given their publically-stated interest in using predictive cell-models as a means of better defining patient populations ahead of expensive clinical trials”

Novartis will pay Horizon undisclosed up-front and renewal fees under the agreement which began in December 2008.